🔎 Trials Near Me

Utama › Penyakit Sel Sabit › Wilayah Columbia › Washington

Kajian klinikal Penyakit Sel Sabit di Washington, DC

20 kajian untuk Penyakit Sel Sabit sedang mencari peserta di lokasi dalam dan sekitar Washington (dalam lingkungan kira-kira 30 batu). Buka kajian untuk melihat siapa yang layak menyertai dan cara menghubungi pasukan kajian.

Teks kajian rasmi (Bahasa Inggeris)

Mengambil peserta untuk kajian di sini? Paparkan di bahagian atas halaman ini — $99 selama 30 hari →

Collection of Human Biospecimens for Basic and Clinical Research Into Globin Variants

Mengambil pesertaKajian pemerhatianSukarelawan sihat dialu-alukan
  • National Institutes of Health Clinical Center, Bethesda · 7 mi jauh
Umur 18 hingga 70 · Semua jantina · Dikemas kini 2 Okt 2026 · NCT03937817

Blood Sampling for Research Related to Sickle Cell Disease

Mengambil pesertaKajian pemerhatianSukarelawan sihat dialu-alukan
  • National Institutes of Health Clinical Center, Bethesda · 7 mi jauh
Umur 18 hingga 100 · Semua jantina · Dikemas kini 29 Sep 2026 · NCT00542230

A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE)

Mengambil pesertaFasa 3
  • Childrens National Hospital, Washington D.C.
Umur 12 hingga 100 · Semua jantina · Dikemas kini 28 Sep 2026 · NCT06439082

Determination of Red Cell Survival in Sickle Cell Disease and Other Hemoglobinopathies Using Biotin Labeling

Mengambil pesertaFasa awal 1
  • National Institutes of Health Clinical Center, Bethesda · 7 mi jauh
Umur 18 hingga 100 · Semua jantina · Dikemas kini 28 Sep 2026 · NCT06313398

Dietary Intake and Dietary Behaviors in Adults With Sickle Cell Disease

Mengambil pesertaKajian pemerhatian
  • National Institutes of Health Clinical Center, Bethesda · 7 mi jauh
Umur 18 hingga 120 · Semua jantina · Dikemas kini 18 Sep 2026 · NCT05170412

Study to Evaluate the Safety and Tolerability of Escalating Doses of Fostamatinib in Subjects With Stable Sickle Cell Disease

Mengambil pesertaFasa 1
  • National Institutes of Health Clinical Center, Bethesda · 7 mi jauh
Umur 18 hingga 65 · Semua jantina · Dikemas kini 17 Sep 2026 · NCT05904093

A Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease

Mengambil pesertaFasa 3
  • Childrens National Medical Ctr, Washington D.C.
  • MedStar Hlth Res Institute, Washington D.C.
Umur 12 ke atas · Semua jantina · Dikemas kini 17 Sep 2026 · NCT06612268

Study to Understand the Genetic Risk of Developing an Immune Response After Blood Transfusions Among Individuals With Sickle Cell Disease

Mengambil pesertaKajian pemerhatian
  • National Institutes of Health Clinical Center, Bethesda · 7 mi jauh
Umur 2 hingga 99 · Semua jantina · Dikemas kini 11 Sep 2026 · NCT06944067

SCD Stem Cell Mobilization and Apheresis Using Motixafortide

Mengambil pesertaFasa 1
  • National Heart, Blood and Lung Institute-Cellular and Molecular Therapy Branch, Bethesda · 7 mi jauh
Umur 18 ke atas · Semua jantina · Dikemas kini 8 Sep 2026 · NCT06442761

Partial Stem Cell Transplant for Sickle Cell Disease From Matched Donors

Mengambil pesertaFasa 1/2
  • National Institutes of Health Clinical Center, Bethesda · 7 mi jauh
Umur 4 hingga 65 · Semua jantina · Dikemas kini 4 Sep 2026 · NCT07599176

Escalating Doses of VAS-101 in Subjects With Stable Sickle Cell Disease

Mengambil pesertaFasa 1
  • National Institutes of Health Clinical Center, Bethesda · 7 mi jauh
Umur 18 hingga 90 · Semua jantina · Dikemas kini 24 Ogo 2026 · NCT07566494

ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders

Mengambil pesertaKajian pemerhatian
  • Georgetown University, Washington D.C.
  • Children's National Hemophilia Center, Washington D.C.
Semua umur · Semua jantina · Dikemas kini 17 Ogo 2026 · NCT04398628

Safety of Anumigilimab (CSL324) in Adults With Sickle Cell Disease (SCD)

Mengambil pesertaFasa 2
  • Center for Cancer and Blood Disorders, Bethesda · 7 mi jauh
Umur 18 ke atas · Semua jantina · Dikemas kini 5 Ogo 2026 · NCT07224360

Cooperative Assessment of Late Effects for SCD Curative Therapies

Mengambil pesertaKajian pemerhatian
  • Children's National Medical Center, Washington D.C.
  • National Institutes of Health Clinical Center, Bethesda · 7 mi jauh
Umur 4 hingga 65 · Semua jantina · Dikemas kini 27 Jul 2026 · NCT05153967

Comparing the Effectiveness of Matched Related Donor Hematopoietic Stem Cell Transplantation to Disease Modifying Therapy in Pediatric Patients With Sickle Cell Disease

Mengambil pesertaKajian pemerhatian
  • Children's National Hospital (MRD-HCT), Washington D.C.
Umur 3 hingga 20 · Semua jantina · Dikemas kini 4 Jun 2026 · NCT06941389

Intravenous L-Citrulline for Vaso-occlusive Pain Episode in Sickle Cell Disease

Mengambil pesertaFasa 2
  • Children's National Hospital, Washington D.C.
Umur 4 hingga 21 · Semua jantina · Dikemas kini 13 Apr 2026 · NCT06635902

Minimizing Toxicity in HLA-identical Sibling Donor Transplantation for Children With Sickle Cell Disease

Mengambil pesertaFasa 2
  • Children's National Health System, Washington D.C.
Umur 2 hingga 25 · Semua jantina · Dikemas kini 10 Mac 2026 · NCT03587272

Sickle Cell Disease Transplant Using a Nonmyeloablative Approach for Patients With Anti-donor Red Cell Antibody

Mengambil pesertaFasa 2
  • Children's National Hospital, Washington D.C.
Umur 2 hingga 25 · Semua jantina · Dikemas kini 26 Sep 2025 · NCT06358638

Advancing Feasibility and Acceptability of Digital Cognitive Rehabilitation in Sickle Cell Disease

Mengambil peserta
  • Children's National Hospital, Washington D.C.
Umur 7 hingga 16 · Semua jantina · Dikemas kini 13 Feb 2025 · NCT06770010

Feasibility and Efficacy of Attentional-Control Training in Sickle Cell Disease

Mengambil peserta
  • Children's National Hospital, Washington D.C.
Umur 8 hingga 16 · Semua jantina · Dikemas kini 10 Jan 2025 · NCT05099874

Kajian Penyakit Sel Sabit di bandar lain

Kajian lain di Washington

Daripada ClinicalTrials.gov, data diperoleh pada 6 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.